BioCentury
ARTICLE | Clinical News

Cubist completes second Cidecin Phase III

July 16, 2001 7:00 AM UTC

CBST completed enrollment in a second Phase III study of its Cidecin daptomycin to treat complicated skin and soft tissue infections (cSST). The primary end point of the U.S. study, which is designed ...